US6700024010
US6700024010
Novavax, Inc.
Loading chart...
Valuation & History
Quarterly trend of key valuation metrics
| Metric | Current (TTM) TTM Baseline | Q2 '26 30.06.2026 | Q1 '26 31.03.2026 | Q4 '25 31.12.2025 |
|---|---|---|---|---|
Market & Enterprise Value | ||||
Market Cap | 2.1B EUR | 1.55B EUR | 1.34B EUR | 1.09B EUR |
Enterprise Value | 1.39B EUR | 1.66B EUR | 1.41B EUR | 1.1B EUR |
Valuation Multiples | ||||
Trailing P/E | -- | -- | -- | -- |
Forward P/E | -77.79x | -- | -- | -- |
Price to Sales | 5.08x | 3.75x | 2.24x | 2.39x |
Price to Book | -- | -- | -- | -- |
EV/Revenue | 3.37x | 4.01x | 2.36x | 2.41x |
EV/EBITDA | -13.73x | -- | 16.64x | 12.95x |
Price to FCF (P/FCF) | 13.71x | -- | -- | -- |
EV/FCF | 9.09x | -- | -- | -- |
FCF Yield | 7.29% | -2.77% | -7.29% | -5.85% |